OGIHealthcare · Drug Manufacturers - Specialty & Generic

OGI Stock Forecast: Organigram Global, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$1.25

+4.17% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 22 Aug 2026 — in the lower half.

Market cap

$176.3M

Ticker Nerd rank

40 / 100

Median analyst target

—

Analysts covering

Total return, dividends reinvested

+1.6%

+32.3%

YTD

−25.6%

−20.4%

From 52W high

−40.8%

From 52W low

+43.5%

$0.87

$2.11

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

OGI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Organigram Global, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions

Size

Growth

Volatility

Value

Quality

Momentum

Issuance

Accruals

Revisions (82): Analysts have, on balance, been raising their forecasts.

Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OGI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OGI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts

4 Buy1 Hold0 Sell

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
17 July 2023	Stifel	Maintains	Buy	$1.25 → $4.00
11 May 2021	CIBC	Upgrade	Neutral	—
14 Apr 2021	CIBC	Downgrade	Underperformer	$5.00 → $3.25
10 Mar 2021	BMO Capital	Downgrade	Underperform	—
9 Jan 2020	Raymond James	Downgrade	Market Perform	—
12 Nov 2019	BMO Capital	Downgrade	Market Perform	—
11 Oct 2019	Jefferies	Upgrade	Buy	—
25 Feb 2019	Jefferies	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OGI appears on the weeks it earns a place.

Estimates

OGI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Organigram Global, Inc. (OGI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 2.8×
Price / sales: 0.6×
Price / book: 0.5×
EV / EBITDA: 15.1×

Growth & margins

Revenue growth (YoY): 49.4%
Earnings growth (YoY): −8.9%
Gross margin: 27.4%
Operating margin: 5.0%
Net margin: 28.0%

Returns & dividend

Return on equity: 17.6%
Return on assets: −0.6%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

OGI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
OGIOrganigram Global, Inc.	$176.3M	40
LFCRLifecore Biomedical, Inc.	$170.1M	4
DERMJourney Medical Corp.	$211.8M	67
CRDLCardiol Therapeutics, Inc.	$217.4M	62
SIGASIGA Technologies, Inc.	$217.8M	42
ORGOOrganogenesis Holdings, Inc.	$228.4M	52
AKBAAkebia Therapeutics, Inc.	$242.9M	75

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Organigram Global, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OGI news & analysis

Organigram Global Accelerates Integration of Sanity Group Under Unified Global Operating Structure

Business Wire · 20 Aug 2026positive

Organigram Global announced an accelerated integration of Sanity Group GmbH under a unified global operating structure, aligning leadership, operations, and market development across the combined organization. The company appointed Finn Age Hänsel as President, Rest of World & Chief Strategy Officer to support the integration.

Why it matters — OGI watchers would care because this milestone advances the company's global growth strategy and consolidates its leadership and operations following the Sanity Group acquisition.

Organigram Global Inc. (OGI:CA) Q3 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Seeking Alpha published the transcript of Organigram Global Inc.'s Q3 2026 earnings call. The item is a transcript of the company's quarterly earnings conference call.

Why it matters — OGI watchers can review management's full remarks and Q&A from the Q3 2026 earnings call to understand the quarter's results and outlook directly from company leadership.

OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

Zacks Investment Research · 11 Aug 2026negative

OrganiGram (OGI) reported a fiscal Q3 quarterly loss of $0.05 per share, wider than the Zacks Consensus Estimate of a $0.01 loss and worse than the $0.03 loss reported a year earlier. The headline indicates the company beat revenue estimates.

Why it matters — OGI watchers would note that the company's per-share loss widened beyond analyst expectations and compared unfavorably with the prior-year period, even as the headline suggests revenue outperformed estimates.

Organigram Global Q3 Earnings Call Highlights

MarketBeat · 11 Aug 2026positive

Organigram Global reported record third-quarter fiscal 2026 revenue and adjusted EBITDA, supported by the consolidation of Germany-based Sanity Group and improving performance in several Canadian cannabis categories.

Why it matters — OGI watchers would care because record revenue and adjusted EBITDA reflect the company's growth from international consolidation and stronger Canadian category performance.

Organigram Reports Record Third Quarter Fiscal 2026 Results

Business Wire · 11 Aug 2026positive

Organigram Global Inc. announced its third quarter fiscal 2026 results for the period ended June 30, 2026, reporting record results with gross revenue of $145.1 million (up 32% year-over-year) and net revenue of $105.8 million (up 49% year-over-year). The company also noted its position as Canada's #1 cannabis company by market share and its acquisition of Sanity Group GmbH.

Why it matters — OGI watchers would care because the company reported record quarterly results with substantial year-over-year revenue growth across both gross and net revenue metrics.

FAQ

Frequently asked questions about OGI stock

Is OGI stock a buy right now?

Of the 5 analysts covering Organigram Global, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Organigram Global, Inc. 40 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OGI?

As at 22 Aug 2026, Organigram Global, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (82 of 100).

What is the OGI stock forecast for 2030?

No analyst covering Organigram Global, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OGI are extrapolating price history, which says nothing about the business.

How has OGI stock performed over the past year?

Organigram Global, Inc. returned -20.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Organigram Global, Inc. do?

Organigram Global Inc. is a leading Canadian cannabis company specializing in the production and sale of medical and recreational cannabis products.

What is the latest news on OGI?

The most recent item we track (Business Wire, 20 Aug 2026): "Organigram Global Accelerates Integration of Sanity Group Under Unified Global Operating Structure". Organigram Global announced an accelerated integration of Sanity Group GmbH under a unified global operating structure, aligning leadership, operations, and market development across the combined organization. The company appointed Finn Age Hänsel as President, Rest of World & Chief Strategy Officer to support the integration.

Company

About Organigram Global, Inc.

Organigram Global Inc. is a leading Canadian cannabis company specializing in the production and sale of medical and recreational cannabis products. Founded in 2010 and headquartered in Toronto, it operates state-of-the-art cultivation and manufacturing facilities across Canada. Organigram’s diverse product portfolio includes whole flower, milled and pre-rolled cannabis, vapes, beverages, gummies, concentrates, and edible products under multiple well-known brands such as SHRED, Holy Mountain, Big Bag O’ Buds, and Edison Cannabis Co. The company utilizes advanced three-tier indoor cultivation technology to optimize quality and yield, alongside dedicated facilities for extraction and product manufacturing. Through innovation and a scientific approach, Organigram is committed to quality, sustainability, and expanding its global reach via strategic international partnerships. It serves both medical and adult-use markets, distributing products through wholesale, retail, and online channels. Organigram plays a significant role in shaping the evolving cannabis industry by driving product development, regulatory advocacy, and responsible cannabis consumption.

CEO Mr. James H. Yamanaka · 1,139 employees · Canada · https://www.organigram.ca